What they were paid
BIOCRYST PHARMACEUTICALS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | — | $0 | $0 | — | — |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOCRYST PHARMACEUTICALS INC DEF 14A filed April 23, 2026, accession 0001628280-26-026822, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025BIOCRYST PHARMACEUTICALS pays directors a $45,000 cash retainer and $325,000 in 60% stock options and 40% RSUs.
The rest of the BIOCRYST PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| A. Machelle Sanders | Independent Director | $385,253 |
| Alan G. Levin | Independent Director | $397,496 |
| Amy E. McKee, M.D | Independent Director | $389,996 |
| Charles K. Gayer | Director | $0 |
| Jill C. Milne, Ph.D | Independent Director | $0 |
| Jon P. Stonehouse | Director | $0 |
| Stephen J. Aselage | Independent Director | $33,475 |
| Steven K. Galson, M.D., MPH | Independent Director | $385,584 |
| Steven R. Frank | Independent Director | $396,489 |
| Theresa M. Heggie | Independent Director | $401,700 |
| Vincent J. Milano | Independent Director | $403,695 |
The full BIOCRYST PHARMACEUTICALS compensation record
free company briefThis page is one director within BIOCRYST PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat